Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LATS1 | O95835 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | PRKCQ | Q04759 | 1/20 | 0.42 |
| ▸ | EIF2AK4 | Q9P2K8 | 1/20 | 0.42 |
| ▸ | CSNK1E | P49674 | 4/20 | 0.41 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | CDK4 | P11802 | 6/20 | 0.39 |
| ▸ | CDK6 | Q00534 | 2/20 | 0.39 |
| ▸ | PIM1 | P11309 | 1/20 | 0.39 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL82946 | 0.79 | HDAC1 (0.45) | LATS1PRKCQEIF2AK4CSNK1EHDAC1 | |
| SCHEMBL18096405 | 0.78 | PLD1 (0.58) | KDM4EPRKCQCSNK1EHDAC1 | |
| Hydrochloric Acid SCHEMBL23124046 | 0.77 | PLD1 (0.57) | KDM4EPRKCQCSNK1EHDAC1 | |
| SCHEMBL16236124 | 0.75 | ALDH1A1 (0.53) | LATS1KDM4EPRKCQEIF2AK4CSNK1E | |
| SCHEMBL26050079 | 0.74 | KDM4E (0.43) | KDM4ELMNAL3MBTL1 | |
| SCHEMBL8040 | 0.74 | PLD1 (0.56) | KDM4ELMNAL3MBTL1PIM1PIM2 | |
| SCHEMBL1477436 | 0.74 | PLD1 (0.56) | KDM4ELMNAL3MBTL1PIM1PIM2 | |
| SCHEMBL29403876 | 0.74 | PLD1 (0.56) | KDM4ELMNAL3MBTL1PIM1PIM2 | |
| Hydrochloric Acid SCHEMBL16236313 | 0.73 | ALDH1A1 (0.56) | LATS1KDM4EPRKCQEIF2AK4CSNK1E | |
| Hydrochloric Acid SCHEMBL27529179 | 0.73 | ALDH1A1 (0.56) | LATS1KDM4EPRKCQEIF2AK4CSNK1E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10301267-B2 | Compounds | ASTRAZENECA AB (SE) | 2019-05-28 | — | — | US | disclosed |
| US-20170260143-A1 | NOVEL COMPOUNDS | ASTRAZENECA AB (SE) | 2017-09-14 | — | — | US | disclosed |
| US-9688640-B2 | Methods of treating cancer with a pyrazole derivative | ASTRAZENECA AB (SE) | 2017-06-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10301267-B2 | Compounds | SLC10A1, CYP11B1, ABCB11 | LATS1 2774/4885KDM4E 2865/4885PRKCQ 4512/4885 |
| US-20170260143-A1 | NOVEL COMPOUNDS | SLC10A1, ABCB11, CYP11B1 | LATS1 2230/4885KDM4E 3393/4885PRKCQ 3087/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.